Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.41USD
3:27pm EDT
Change (% chg)

$-0.01 (-3.42%)
Prev Close
$0.43
Open
$0.42
Day's High
$0.43
Day's Low
$0.41
Volume
34,237
Avg. Vol
127,662
52-wk High
$8.70
52-wk Low
$0.31

Latest Key Developments (Source: Significant Developments)

Cytori Therapeutics Says Cancer Treatment Receives FDA Orphan Drug Designation
Monday, 17 Sep 2018 09:28am EDT 

Sept 17 (Reuters) - Cytori Therapeutics Inc ::PHASE 2 READY ONCOLOGY DRUG RECEIVES FDA ORPHAN DRUG DESIGNATION.CYTORI THERAPEUTICS INC - RECEIVED FDA ORPHAN DRUG DESIGNATION FOR ITS ATI-1123 CHEMOTHERAPY DRUG PRODUCT CANDIDATE.  Full Article

Cytori Therapeutics - Entered Second Amendment To Its Existing Loan And Security Agreement
Wednesday, 20 Jun 2018 09:24am EDT 

June 20 (Reuters) - Cytori Therapeutics Inc ::CYTORI THERAPEUTICS INC - ON JUNE 19, ENTERED SECOND AMENDMENT TO ITS EXISTING LOAN AND SECURITY AGREEMENT, DATED MAY 29, 2015- SEC FILING.CYTORI THERAPEUTICS INC - THE SECOND AMENDMENT EXTENDS INTEREST-ONLY PERIOD UNDER LOAN AGREEMENT TO AUGUST 1, 2018.  Full Article

Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin
Monday, 30 Apr 2018 08:30am EDT 

April 30 (Reuters) - Cytori Therapeutics Inc ::CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN.CYTORI THERAPEUTICS - INTENDS TO FIRST SEEK EUROPEAN APPROVAL FOR ITS DRUG, APPLIED FOR, GOT EMA APPROVAL TO FILE FOR CENTRALIZED EU APPROVAL.  Full Article

Cytori Q4 Adjusted Loss Per Share $0.10
Thursday, 8 Mar 2018 04:25pm EST 

March 8 (Reuters) - Cytori Therapeutics Inc ::CYTORI REPORTS FOURTH QUARTER AND FULL YEAR 2017 BUSINESS AND FINANCIAL RESULTS.Q4 ADJUSTED LOSS PER SHARE $0.10.Q4 LOSS PER SHARE $0.20.Q4 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.  Full Article

Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
Monday, 8 Jan 2018 03:23pm EST 

Jan 8 (Reuters) - Cytori Therapeutics Inc ::SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​.  Full Article

Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​
Monday, 13 Nov 2017 09:00am EST 

Nov 13 (Reuters) - Cytori Therapeutics Inc :Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​.  Full Article

Cytori reports Q3 loss per share $0.14
Thursday, 9 Nov 2017 04:25pm EST 

Nov 9 (Reuters) - Cytori Therapeutics Inc :Cytori reports third quarter 2017 business and financial results.Q3 loss per share $0.14.Cytori Therapeutics Inc - ‍received U.S. FDA IDE approval for relief, a thermal burn pilot trial related to ongoing barda contract​.Cytori Therapeutics Inc - ‍expects full year 2017 operating cash burn to be lower than 2016, primarily due to restructuring announced in September 2017​.  Full Article

Cytori announces corporate restructuring & cost reduction plan
Friday, 1 Sep 2017 04:15pm EDT 

Sept 1 (Reuters) - Cytori Therapeutics Inc :Cytori announces corporate restructuring & cost reduction plan.Cytori announces corporate restructuring & cost reduction plan.Cytori Therapeutics Inc - ‍restructuring is expected to reduce Cytori's workforce by approximately 50% and significantly reduce quarterly operational cash burn​.Cytori Therapeutics - habeo program for scleroderma is expected to move forward based on feedback from forthcoming meetings with FDA in U.S., PMDA in Japan​.Cytori Therapeutics Inc - ‍company and its advisors, tap advisors, will consider a range of options including a sale of company and a reverse merger​.Cytori Therapeutics Inc - ‍announced a substantial corporate restructuring intended to significantly reduce expenses​.Cytori Therapeutics Inc says ‍have engaged tap advisors to "help us evaluate several potential opportunities company has​".Cytori Therapeutics - ‍restructuring while maintaining ability to execute on its BARDA-sponsored cell therapy program, japanese business, oncology program​.  Full Article

Cytori Therapeutics Q2 loss per share $0.19
Thursday, 10 Aug 2017 04:25pm EDT 

Aug 10 (Reuters) - Cytori Therapeutics Inc :Cytori reports second quarter 2017 business and financial results.Q2 loss per share $0.19.Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Cytori Therapeutics Inc - expects full year 2017 operating cash burn to be higher than 2016.Says Q2 2017 total revenues were $1.5 million compared to $2.8 million for same periods in 2016.Cytori Therapeutics Inc - full year 2017 updated operating cash burn forecasted to be within a range of $20 million to $23 million.  Full Article

Cytori announces top-line 24- and 48-week results
Monday, 24 Jul 2017 08:00am EDT 

July 24 (Reuters) - Cytori Therapeutics Inc ::Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma.Cytori Therapeutics Inc - ‍clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup​.Cytori Therapeutics Inc - statistical significance not achieved in primary or secondary efficacy endpoints.Cytori Therapeutics Inc - intends to submit full star data set to American College Of Rheumatology meeting in November 3-8, 201.  Full Article

BRIEF-Cytori Therapeutics Common Stock To Begin Trading On Adjusted Basis On May 24

* CYTORI THERAPEUTIC’S COMMON STOCK TO BEGIN TRADING ON ADJUSTED BASIS ON MAY 24, FOLLOWING ONE-FOR-TEN REVERSE SPLIT Source text for Eikon: Further company coverage: